Equity Profile

BMRN

BioMarin Pharmaceutical Inc.

Health CareBiotechnology$13.3B

Aug3Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing innovative therapies for rare genetic diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$0.95

Revenue

Revenue figures help assess the company's sales performance and market demand for its products.

$932M

Wall Street expectations, options signals, track record, and call prep available with Pro.

BMRN Q2-2026 Earnings Preview

Context

Company Snapshot

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing innovative therapies for rare genetic diseases. With a market cap of $13 billion, it plays a crucial role in the healthcare sector by providing treatments that address unmet medical needs.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+117.28%

Avg Stock Reaction

-0.49%

Last Quarter Recap

In Q1 2026, BioMarin reported an EPS of $0.76, slightly below the estimate of $0.78, leading to a modest stock increase of 2.59% the following day. The company continues to navigate challenges in meeting revenue expectations.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect BioMarin to report earnings that align closely with consensus estimates, reflecting cautious optimism in the market. The company has a history of beating EPS estimates, which could influence investor sentiment.

Bull Case

If BioMarin exceeds the EPS estimate, it could signal strong demand for its products and effective cost management, potentially boosting the stock price significantly.

Bear Case

Conversely, if the company misses expectations again, it may raise concerns about its growth trajectory and ability to compete in the biotechnology sector, leading to a negative reaction from investors.

Key Metrics to Watch

EPS

$0.95

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$932M

Revenue figures help assess the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $0.95?

A beat on EPS could indicate strong operational performance and boost investor confidence.

What are the revenue projections for key products this quarter?

Understanding revenue contributions from major products will help gauge market demand and growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the impact of recent product launches, which could drive higher-than-expected revenue growth.

Supporting Evidence

BioMarin has a strong track record of beating EPS estimates, with a 75% success rate over the last eight quarters.

The options market is pricing a larger move than historical averages, suggesting potential volatility that could favor a positive surprise.

Key Risk

If revenue from new products significantly exceeds expectations, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching BioMarin's ability to meet or exceed earnings expectations, given its recent mixed performance.

Bull Confirmed If

An EPS of $1.00 or higher would confirm strong demand and operational efficiency.

Bear Confirmed If

An EPS below $0.80 would raise concerns about the company's growth and market position.

Pre-Earnings Positioning

Options Market

Implied Move

±15.32%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant potential movement in the stock price following the earnings report, indicating heightened investor uncertainty.

Options are pricing ±15.3% while BMRN has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

42.3%

Calls (10K)P/C Ratio: 0.20Puts (4K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioMarin beats expectations, history suggests a potential stock increase of around 2.36%, confirming bullish sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see minimal movement as investors await further guidance.

Miss

A miss could lead to a decline of approximately 0.37% based on historical patterns, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the performance of key products and their contribution to revenue.
2Any updates on regulatory approvals for upcoming therapies.
3Management's outlook on market conditions and competitive landscape.
4Insights into cost management strategies and operational efficiency.
5Guidance on future earnings expectations and product pipeline developments.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing innovative therapies for rare genetic diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of the company's profitability and financial health.

$0.95

Revenue

Revenue figures help assess the company's sales performance and market demand for its products.

$932M

Wall Street expectations, options signals, track record, and call prep available with Pro.

BMRN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+117.28%

Avg Stock Reaction

-0.49%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If BioMarin exceeds the EPS estimate, it could signal strong demand for its products and effective cost management, potentially boosting the stock price significantly.

Bear Case

Key Metrics to Watch

EPS

$0.95

Earnings per share is a key indicator of the company's profitability and financial health.

Revenue

$932M

Revenue figures help assess the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the consensus estimate of $0.95?

A beat on EPS could indicate strong operational performance and boost investor confidence.

What are the revenue projections for key products this quarter?

Understanding revenue contributions from major products will help gauge market demand and growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate the impact of recent product launches, which could drive higher-than-expected revenue growth.

Supporting Evidence

BioMarin has a strong track record of beating EPS estimates, with a 75% success rate over the last eight quarters.

The options market is pricing a larger move than historical averages, suggesting potential volatility that could favor a positive surprise.

Key Risk

If revenue from new products significantly exceeds expectations, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is closely watching BioMarin's ability to meet or exceed earnings expectations, given its recent mixed performance.

Bull Confirmed If

An EPS of $1.00 or higher would confirm strong demand and operational efficiency.

Bear Confirmed If

An EPS below $0.80 would raise concerns about the company's growth and market position.

Pre-Earnings Positioning

Options Market

Implied Move

±15.32%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant potential movement in the stock price following the earnings report, indicating heightened investor uncertainty.

Options are pricing ±15.3% while BMRN has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

42.3%

Calls (10K)P/C Ratio: 0.20Puts (4K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioMarin beats expectations, history suggests a potential stock increase of around 2.36%, confirming bullish sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may see minimal movement as investors await further guidance.

Miss

A miss could lead to a decline of approximately 0.37% based on historical patterns, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on the performance of key products and their contribution to revenue.
2Any updates on regulatory approvals for upcoming therapies.
3Management's outlook on market conditions and competitive landscape.
4Insights into cost management strategies and operational efficiency.
5Guidance on future earnings expectations and product pipeline developments.